We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) TM in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMAR xT Tissue-Specific TM Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. We use systems biology principles for rapid candidate selection and effective pre-clinical studies, leading to efficient manufacturing/scale up processes, toxicology and IP, followed by selection of appropriate contract research organizations and high-speed enrollment clinical trial sites.

ImmixBio Announces Dr. Jane Buchan Joins Board of Directors News provided byImmix Biopharma, Inc. Jul 28, 2021, 08:48 ET LOS ANGELES, July 28, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)™ for oncology and inflammation, today announced that world-renown institutional […]
ImmixBio Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering News provided byImmix Biopharma, Inc.Jul 23, 2021, 08:38 ET LOS ANGELES, July 23, 2021 /PRNewswire/ — Immix Biopharma, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 […]
ImmixBio Announces Helen C. Adams Joins Board of Directors News provided by Immix Biopharma, Inc. Jul 13, 2021, 08:11 ET LOS ANGELES, July 13, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue-Specific Therapeutics (TSTx)â„¢ for oncology and inflammation, today announced that accounting […]